TTRX — Turn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023016 ·
Last close
$9.44
Market Cap
$281.20M
52W High
$11.69
52W Low
$3.14
ADV30
91,349
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Sep 2025 | — | — | — | — | — | — | — |
| Jun 2025 | 0 | — | -1,366,524 | -1,240,415 | 4,331,302 | 3,189,943 | 2,556,806 |
| Mar 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-20,764,985
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-1,366,524
Pretax Income TTM
$-1,240,415
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | — | — | — |
| Dec 2024 | 0 | -1,797,124 | -1,768,415 | 2,048,889 | 2,226,321 | — | -1,361,305 |
| Dec 2023 | 0 | -2,308,149 | -2,292,267 | 2,013,560 | 1,927,792 | — | -1,377,680 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNAC | Cartesian Therapeutics, Inc. | $277.95M | $9.46 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $285.95M | $2.12 | — |
| PRE | Prenetics Global Ltd | $275.39M | $17.86 | — |
| MGNX | MACROGENICS INC | $275.23M | $4.33 | — |
| GLSI | Greenwich LifeSciences, Inc. | $290.63M | $19.80 | — |
News headlines (Yahoo Finance, 1h cache)
Turn Therapeutics’ stock jumps on AD data and trial expansion
2026-07-08 11:17 · Yahoo
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis
2026-07-07 12:56 · Yahoo
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
2026-07-07 12:05 · Yahoo
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
2026-07-06 20:01 · Yahoo
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
2026-06-01 12:30 · Yahoo
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
2026-03-02 06:08 · Yahoo
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock
2026-02-04 13:17 · Yahoo
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying
2026-01-08 12:13 · Yahoo
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
2026-01-07 21:05 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
2025-12-29 12:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.